PI3K and cancer: lessons, challenges and opportunities

@article{Fruman2014PI3KAC,
  title={PI3K and cancer: lessons, challenges and opportunities},
  author={David A Fruman and Christian Rommel},
  journal={Nature Reviews Drug Discovery},
  year={2014},
  volume={13},
  pages={140-156}
}
The central role of phosphoinositide 3-kinase (PI3K) activation in tumour cell biology has prompted a sizeable effort to target PI3K and/or downstream kinases such as AKT and mammalian target of rapamycin (mTOR) in cancer. However, emerging clinical data show limited single-agent activity of inhibitors targeting PI3K, AKT or mTOR at tolerated doses. One exception is the response to PI3Kδ inhibitors in chronic lymphocytic leukaemia, where a combination of cell-intrinsic and -extrinsic activities… CONTINUE READING
Highly Influential
This paper has highly influenced 26 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 26 times over the past 90 days. VIEW TWEETS
384 Citations
244 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 384 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 244 references

Inhibition of the p110α isoform of PI3‐ kinase stimulates nonfunctional tumor angiogenesis

  • A Soler
  • J. Exp. Med
  • 2013
Highly Influential
11 Excerpts

Similar Papers

Loading similar papers…